Last updated on November 2017

A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Ulcerative Colitis


Brief description of study

A Phase 3 Clinical Trial for Patients with Moderately to Severely Active Ulcerative Colitis

Detailed Study Description

To assess the effect of vedolizumab SC maintenance treatment on clinical remission at Week 52 in subjects with moderately to severely active UC who achieved clinical response at Week 6 following administration of vedolizumab IV at Weeks 0 and 2.

Clinical Study Identifier: TX15254

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )